CEO of Nasdaq-Listed Cell Immunotherapy Company Enlivex Steps Down
Enlivex develops cell-based treatments for life-threatening immune and inflammatory conditions, such as graft versus host disease, a post bone marrow transplant complication
Name: Schmuel Hess
Continent: Asia
Country: Israel
Company: Enlivex Therapeutics Ltd.
Position: CEO
Reason: Resigned
Announcement Date: October 01, 2019, 10:00pm
Resignation Date:
Source 1: https://www.calcalistech.com/ctech/articles/0,7340,L-3771329,00.html